Cancer Research

Analysis shows fluorouracil remains in bloodstream longer when administered with Davanat

Published in Cancer Weekly, November 8th, 2005

Pro-Pharmaceuticals, Inc. (PRW) announced that the pharmacokinetics analysis of cancer patients in the sixth and final cohort of phase I indicates 5-fluorouracil (5-FU) remained in the bloodstream significantly longer when co-administered with Davanat, thereby potentially increasing 5-FU's efficacy while lowering its toxicity.

Specific pharmacokinetics data includes:

-5-FU was administered at a dose of 500 mg/m². As body surface area of the patients ranged between 1.55 and 2.38 m², the actual 5-FU administered to certain cancer patients ranged between 775 and 1,190 mg/m² per day for 4 consecutive days.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-11-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry